论文部分内容阅读
目的:研究胃癌患者血清可溶性ICAM-1(sICAM-1)的变化与胃癌,临床病理因素的关系。 方法:采用酶联免疫吸附试验法检测了68例胃癌患者及42例正常对照者血清sICAM-1的浓度。数据分析采用非配对t检验。 结果:胃癌患者血清sICAM-1的水平为233μg·L~(-1)±46μg·L~(-1),高于正常对照者209μg·L~(-1)±35μg·L~(-1),P<0.05);晚期胃癌比早期胃癌血清sICAM-1的水平高,有肝转移、淋巴结转移的胃癌患者血清sICAM-1的浓度较无转移者明显升高249μg·L~(-1)±46μg·L~(-1),P<0.01),而肠型胃癌和弥散型胃癌患者血清sICAM-1的平均浓度无明显差别(P=0.054)。 结论:胃癌患者血清sICAM-1的水平升高,且预后不良。血清sICAM-1水平的升高可能在胃癌的进展和转移过程中起重要作用。
Objective: To study the relationship between the changes of serum soluble ICAM-1 (sICAM-1) and gastric cancer and clinicopathological factors in patients with gastric cancer. Methods: The serum concentrations of sICAM-1 in 68 patients with gastric cancer and 42 healthy controls were detected by enzyme-linked immunosorbent assay. Data analysis using unpaired t-test. Results: Serum levels of sICAM-1 in patients with gastric cancer were 233μg · L -1 ± 46μg · L -1, which were significantly higher than those of 209μg · L -1 ± 35μg · L -1 ), P <0.05). Serum levels of sICAM-1 in advanced gastric cancer were higher than those in early gastric cancer. Serum levels of sICAM-1 in patients with liver metastasis and lymph node metastasis were significantly higher than those without metastasis (249μg · L -1) ± 46μg · L -1, P <0.01). However, there was no significant difference in serum sICAM-1 between intestinal-type gastric cancer and diffuse gastric cancer (P = 0.054). Conclusion: The serum level of sICAM-1 in patients with gastric cancer is elevated, and the prognosis is poor. Elevated serum levels of sICAM-1 may play an important role in the progression and metastasis of gastric cancer.